About: Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines
Creator	Kanekiyo, Masaru Veesler, David Baker, David Park, Young-Jun Mascola, John Watson, Michael Crank, Michelle Graham, Barney Moin, Syed Lee, Kelly Stewart, Lance Ellis, Daniel King, Neil Boyoglu-Barnum, Seyhan Carter, Lauren Gillespie, Rebecca Guttman, Miklos Hutchinson, Geoffrey Pettie, Deleah Ravichandran, Rashmi Vaile, John Murphy, Mike Acton, Oliver Creanga, Adrian Kephart, Sally Matheson, Nick Ueda, George
Source	BioRxiv
abstract	Influenza vaccines that confer broad and durable protection against diverse virus strains would have a major impact on global health. However, next-generation vaccine design efforts have been complicated by challenges including the genetic plasticity of the virus and the immunodominance of certain epitopes in its glycoprotein antigens. Here we show that computationally designed, two-component nanoparticle immunogens induce potently neutralizing and broadly protective antibody responses against a wide variety of influenza viruses. The nanoparticle immunogens display 20 hemagglutinin (HA) trimers in a highly immunogenic array, and their assembly in vitro enables precisely controlled co-display of multiple distinct HAs in defined ratios. Nanoparticle immunogens displaying the four HAs of licensed quadrivalent influenza vaccines (QIV) elicited hemagglutination inhibition and neutralizing antibody responses to vaccine-matched strains that were equivalent or superior to commercial QIV in mice, ferrets, and nonhuman primates. The nanoparticle immunogens—but not QIV—simultaneously induced broadly protective antibody responses to heterologous viruses, including H5N1 and H7N9, by targeting the subdominant yet conserved HA stem. Unlike previously reported influenza vaccine candidates, our nanoparticle immunogens can alter the intrinsic immunodominance hierarchy of HA to induce both potent receptor-blocking and broadly cross-reactive stem-directed antibody responses and are attractive candidates for a next-generation influenza vaccine that could replace current seasonal vaccines. One Sentence Summary Nanoparticle immunogens displaying four seasonal influenza hemagglutinins elicit neutralizing antibodies directed at both the immunodominant head and the conserved stem and confer broad protective immunity.
has issue date	2020-05-31(xsd:dateTime)
bibo:doi	10.1101/2020.05.30.125179
has license	biorxiv
sha1sum (hex)	3fd0c5cfdbb002c35e71e763b29e460aadc988b8
schema:url	https://doi.org/10.1101/2020.05.30.125179
resource representing a document's title	Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines
schema:publication	bioRxiv
resource representing a document's body	covid:3fd0c5cfdbb002c35e71e763b29e460aadc988b8#body_text
is schema:about of	named entity '450 nm' named entity 'nanoparticle' named entity 'epitopes' named entity 'virus' named entity 'Fab fragments' named entity 'cross-reactive' named entity 'nanoparticle' named entity 'virus' named entity 'beam tilt' named entity 'influenza' named entity 'acetonitrile' named entity 'pH 3' named entity 'cell lysate' named entity 'nanoparticle' named entity 'intramuscularly' named entity 'viruses' named entity 'nanoparticle' named entity 'H3N2' named entity 'cross-reactive' named entity 'serum' named entity 'Serum samples' named entity 'formic acid' named entity 'titer' named entity 'vaccine manufacturing' named entity 'vaccine' named entity 'cryo-EM' named entity 'Immune sera' named entity 'H3N2' named entity 'low-pass filter' named entity 'endotoxin' named entity 'virus' named entity 'Fourier shell correlation' named entity '2.0' named entity 'immunogenic' named entity 'mAbs' named entity 'Immunoprecipitation' named entity 'Fourier shell correlation' named entity 'influenza viruses' named entity 'single-particle reconstruction' named entity 'antigen' named entity 'immunogens' named entity 'protein' named entity 'DTT' named entity 'virus' named entity 'InvivoGen' named entity 'Immunization' named entity 'weight loss' named entity 'broadly neutralizing antibodies' named entity 'infection' named entity 'immunization' named entity 'PerkinElmer' named entity 'squalene' named entity 'sonication' named entity 'H7N9' named entity 'H3N2' named entity 'SEC' named entity 'mass spectrometer' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software